Advertisement
News
Subscribe to MDT Magazine News

Amarin says treatment cuts triglycerides in Phase 3 trial

April 18, 2011 9:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Amarin Corp., an Irish biopharmaceutical with U.S. operations in Mystic, Conn., said today that its drug candidate AMR101 showed significant decreases in triglycerides during a Phase 3 trial.

TOPICS:

JCI online early table of contents: April 18, 2011

April 18, 2011 8:38 am | by EurekAlert | Comments

(Journal of Clinical Investigation) This release contains the summaries, titles and author contact information for articles to be released in the April 18 edition of the JCI, including "Why the immune system attacks beta cells in Type 1 diabetes"; "Could a liver cell transplant...

TOPICS:

Manufacturers to Discover Latest Technologies at HOUSTEX April 18-20, George R. Brown Convention Center

April 18, 2011 8:37 am | by Society of Manufacturing Engineers | Comments

DEARBORN, Mich., April 18, 2011 — With the manufacturing sector leading the country's economic recovery, it is imperative for manufacturers to stay on top of the latest technologies and processes. With more than 13,000 manufacturing and engineering companies in the greater Houston...

Advertisement

Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns

April 18, 2011 8:34 am | by Bio-Medicine.Org | Comments

WATERTOWN, Mass., April 18, 2011 /- Measuring the body temperatures of newborns with temporal artery thermometry (forehead scanning) provides readings comparable to results obtained by axillary (under arm) thermometry, the clinically recommended method for this patient population, but...

TOPICS:

Bedford Laboratoriesâ„¢ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial

April 18, 2011 8:34 am | by Bio-Medicine.Org | Comments

BEDFORD, Ohio,  April 18, 2011 /- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio.  Topotecan is AP Bioequivalent to the reference...

TOPICS:

Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011

April 18, 2011 8:33 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, April 18, 2011 /- Luminex Corporation (Nasdaq: LMNX ) today announced that it expects to report results for the first quarter of 2011 on Monday, May 9, 2011. A press release announcing the results is scheduled for release after the close of trading. (Logo:  ...

TOPICS:

Roche Launches EMR Interface for VA to Facilitate Diabetes Management

April 18, 2011 8:33 am | by Bio-Medicine.Org | Comments

INDIANAPOLIS, April 18, 2011 /- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has introduced a new Electronic Medical Record (EMR) interface for the U.S. Department of Veterans Affairs (VA) that helps VA healthcare facilities improve their efficiency and accuracy by...

TOPICS:

Amedisys to buy Beacon Hospice for $125 million

April 18, 2011 7:45 am | by The Associated Press | Comments

Home health services provider Amedisys Inc. said Monday that it has agreed to buy Boston-based hospice company Beacon Hospice for about $125 million.Beacon has 23 free-standing locations and one inpatient unit, serving the states of Massachusetts, Maine, New Hampshire, Rhode Island and Connecticut....

Advertisement

Summary Box: Community Health makes new Tenet bid

April 18, 2011 7:45 am | by The Associated Press | Comments

TAKE TWO: Hospital operator Community Health Systems Inc. revised its bid for Tenet Healthcare Corp. Monday and is now proposing a deal worth about $3 billion in cash.THE CHANGE: The offer still values Tenet at $6 per share. Community Health had offered to buy Tenet for $5 per share in cash and...

BB & T Advises Dr. Comfort on Its Sale to DJO Global in Transaction Valued at $254.6 Million

April 18, 2011 6:38 am | by Bio-Medicine.Org | Comments

RICHMOND, Va., April 18, 2011 /- BB&T Capital Markets served as the exclusive financial advisor to Rikco International LLC, d/b/a Dr. Comfort, the leading developer, manufacturer and marketer of therapeutic footwear and related medical and comfort products, in its sale to DJO Global,...

TOPICS:

Australian Center Readies Brain Research Program for Addition of Elekta MEG System

April 18, 2011 6:36 am | by Bio-Medicine.Org | Comments

MELBOURNE, Australia, April 18, 2011 /- Certain brain processes happen in the blink of an eye – and even faster – which has made pinpointing these events virtually impossible. The advent of magnetoencephalography (MEG) changed all that, enabling researchers to capture brain...

TOPICS:

Symmetry Medical to Report First Quarter 2011 Financial Results on May 5, 2011

April 18, 2011 6:35 am | by Bio-Medicine.Org | Comments

WARSAW, Ind., April 18, 2011 /- Symmetry Medical Inc. (NYSE: SMA ), a leading independent provider of products to the global orthopaedic device industry and other medical markets, announced today that it will release first quarter 2011 financial results for the period ending April 2, 2011...

TOPICS:

CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation

April 18, 2011 6:35 am | by Bio-Medicine.Org | Comments

ATLANTA and IRVINE, Calif., April 18, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the expiration of the 20-day "go-shop" period that is part of its definitive agreement with Cardiogenesis...

TOPICS:

Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient

April 18, 2011 6:34 am | by Bio-Medicine.Org | Comments

GAITHERSBURG, Md., April 18, 2011 /- Sigma-Tau Pharmaceuticals, Inc. is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture L-asparaginase, the primary ingredient in the oncology medicine ONCASPAR® (pegaspargase)....

TOPICS:

InstaCare Subsidiary Signs New Agreement for Expanded Management and Sales of Shasta Genstrip Into the $20 Billion Worldwide Diabetes Testing Market

April 18, 2011 6:32 am | by Bio-Medicine.Org | Comments

LOS ANGELES, April 18, 2011 /- InstaCare Corp. (OTCQB: ISCR) a leading provider of prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading